Brief: Aquestive Therapeutics Announces FDA Acceptance Of Anaphylm™ NDA Resubmission And PDUFA Goal Date Of March 16, 2027
15/10/2026 13:45
BRIEF-Aquestive Therapeutics Announces FDA Acceptance Of Anaphylm™ NDA Resubmission And PDUFA Goal Date Of March 16, 2027 Oct 15 (Reuters) - Aquestive Therapeutics, Inc. AQST.O:
AQUESTIVE THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF ANAPHYLM™ NDA RESUBMISSION AND PDUFA GOAL DATE OF MARCH 16, 2027
AQUESTIVE THERAPEUTICS - PDUFA GOAL ACTION DATE FOR ANAPHYLM SET FOR MARCH 16, 2027
AQUESTIVE THERAPEUTICS - CANADIAN NEW DRUG SUBMISSION FOR ANAPHYLM PLANNED FOR Q4 2026
Source text: ID:nGNXccNZVk
Further company coverage: AQST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Announces FDA Acceptance Of Anaphylm™ NDA Resubmission And PDUFA Goal Date Of March 16, 2027
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Aquestive rises on US licensing deal for seizure drug with Eton Pharma